生物藥學專題討論

08/09(一) 10:10 詹又臻 Dr.黃奇英 Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer Nature Communications volume 12, Article number: 2383 (2021) Dr.黃奇英 Dr.蘇瑀 Dr.蕭崇瑋

08/13(五) 10:10 林暄祐 Dr.金翠庭 FTO-mediated cytoplasmic m6Am demethylation adjusts stem-like properties in colorectal cancer cell Nature Communications volume 12, Article number: 1716 (2021) Dr.蘇瑀 Dr.蕭崇瑋

08/18(三) 10:10 黃榮美 Dr.劉俊煌 Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination Nature Communications volume 12, Article number: 2626 (2021) Dr.劉俊煌 Dr.蕭崇瑋 Dr.蘇瑀

10/05(二) 王宇家 Dr.林照雄 Human ribonuclease 1 serves as a secretory ligand of ephrin A4 receptor and induces breast tumor initiation Nat Commun. 2021 May 13;12(1):2788. Dr.蘇瑀 Dr.蕭崇瑋 Dr.何國牟 Dr.金翠庭

10/12(二) 陳立洲 Dr.劉俊煌 Single residue in CD28-costimulated CAR-T cells limits long term persistence and antitumor durability J Clin Invest. 2020;130(6):3087-3097. Dr.劉俊煌 Dr.蘇瑀 Dr.蕭崇瑋 Dr.何國牟 Dr.金翠庭

10/19(二) 詹雅倫 Dr.劉俊煌 Identification of CD318, TSPAN8 and CD66c as target candidates for CAR T cell based immunotherapy of pancreatic adenocarcinoma Nature Communications (2021) 12:1453 Dr.劉俊煌 Dr.蘇瑀 Dr.蕭崇瑋 Dr.何國牟 Dr.金翠庭

11/02(二) 期中考周

11/16(二) 曾馨儀 Dr.蕭崇瑋 Dr.蘇溶真 Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition Sci Adv. 2020 Jun 17;6(25):eabb2210. Dr.劉俊煌 Dr.蘇瑀 Dr.蕭崇瑋 Dr.何國牟 Dr.金翠庭

11/23(二) 周慈慧 Dr.蘇瑀 Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy Nature Communications volume 12, Article number: 832 (2021) Dr.劉俊煌 Dr.蘇瑀 Dr.蕭崇瑋 Dr.金翠庭

11/30(二) 林安俞 Dr.蘇瑀 Drug-resistant cancer cell-derived exosomal EphA2 promotes breast cancer metastasis via the EphA2-Ephrin A1 reverse signaling Cell Death Dis. Article number: 12 (2021) Dr.蘇瑀 Dr.蕭崇瑋 Dr.金翠庭

12/28(二) 期末考周